Trial Profile
An Open-label, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two Batches of the Same Fixed Dose Combinations Amaryl M IR 2/1000 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glimepiride/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 16 Sep 2020 Planned End Date changed from 1 May 2015 to 1 Dec 2015.
- 16 Sep 2020 Planned initiation date changed from 1 Apr 2015 to 1 May 2015.
- 16 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.